Efficacy and Safety Evaluation of Nabilone as Adjunctive Therapy to Gabapentin for the Management of Neuropathic Pain in Multiple Sclerosis
What it found
We found no results in the registry or in papers.
This trial finished 14 years ago. We found no results in the registry or in any paper that cites it.
What was tested
Treatment tested
- Nabilone
Cannabinoid CB1 receptor agonist
Placebo or sham
- placebo
What it measured
Main measures
VAS
9 weeks
Other measures (3)
SF MPQ
9 weeks
SF-36
9 weeks
Quality of life (reported by participants)PGIC
9 weeks
Who could take part
Relapsing MS · 18 to 65
Inclusion Criteria: * Males and females between the ages of 18-65 years old with clinically definite RRMS * EDSS of \< 6.5 * Current treatment with gabapentin that is not effective at a stabilized dose of (>1800mg/day) for at least 1 month. * Visual Analogue Scale score for NPP symptoms > 5; pain present for at least 3 months * Negative serum pregnancy test for all females of childbearing age; not currently breastfeeding * No history of alcohol or substance abuse * No history of non-psychotic emotional disorders * No significant hepatic or renal insufficiency * No significant cardiovascular disease or hypertension * No known hypersensitivity and/or allergy to nabilone or its derivatives * No current use of cannabinoid or related products
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
The purpose of this study is to determine whether nabilone (Cesamet) when used as an adjunctive agent with gabapentin (Neurontin) provides significantly improved pain relief over gabapentin alone for the management of neuropathic pain in MS.
Loading reviews and guidelines…
Related trials
- CUEBS
Phase 4 · Completed
No result found
History
Started
Jun 2007
Main results due
Jul 2012
Finished
Jul 2012
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error